{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:22:08Z","timestamp":1792264928713,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10147-025-02776-4","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T12:50:13Z","timestamp":1747486213000},"page":"1505-1521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Stereotactic body radiotherapy for oligometastatic disease: current evidence and future perspectives"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7668-1506","authenticated-orcid":false,"given":"Nobuki","family":"Imano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"key":"2776_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8\u201310. https:\/\/doi.org\/10.1200\/JCO.1995.13.1.8","journal-title":"J Clin Oncol"},{"key":"2776_CR2","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Lievens Y, Bouma AB et al (2020) Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 21:e18\u2013e28. https:\/\/doi.org\/10.1016\/S1470-2045(19)30718-1","journal-title":"Lancet Oncol"},{"key":"2776_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","volume":"148","author":"Y Lievens","year":"2020","unstructured":"Lievens Y, Guckenberger M, Gomez D et al (2020) Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol 148:157\u2013166. https:\/\/doi.org\/10.1016\/j.radonc.2020.04.003","journal-title":"Radiother Oncol"},{"key":"2776_CR4","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jtho.2019.07.025","volume":"14","author":"AC Dingemans","year":"2019","unstructured":"Dingemans AC, Hendriks LEL, Berghmans T et al (2019) Definition of synchronous oligometastatic non-small cell lung cancer: a consensus report. J Thorac Oncol 14:2109\u20132119. https:\/\/doi.org\/10.1016\/j.jtho.2019.07.025","journal-title":"J Thorac Oncol"},{"key":"2776_CR5","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.3390\/cancers14051152","volume":"14","author":"R Kinj","year":"2022","unstructured":"Kinj R, Muggeo E, Schiappacasse L et al (2022) Stereotactic body radiation therapy in patients with oligometastatic disease: clinical state of the art and perspectives. Cancers (Basel) 14:1152. https:\/\/doi.org\/10.3390\/cancers14051152","journal-title":"Cancers (Basel)"},{"key":"2776_CR6","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393:2051\u20132058. https:\/\/doi.org\/10.1016\/S0140-6736(18)32487-5","journal-title":"Lancet"},{"key":"2776_CR7","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA, Olson R, Harrow S et al (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 38:2830\u20132838. https:\/\/doi.org\/10.1200\/JCO.20.00818","journal-title":"J Clin Oncol"},{"key":"2776_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(23)08702-9","volume":"182","author":"V Khoo","year":"2023","unstructured":"Khoo V, Kirby A, Ahmed M et al (2023) CORE - Standard of care +\/- stereotactic body radiotherapy for oligometastases: primary results. Radiother Oncol 182:s627. https:\/\/doi.org\/10.1016\/S0167-8140(23)08702-9","journal-title":"Radiother Oncol"},{"key":"2776_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ijrobp.2024.08.031","volume":"121","author":"D Schellenberg","year":"2025","unstructured":"Schellenberg D, Gabos Z, Duimering A et al (2025) Stereotactic ablative radiation for oligoprogressive cancers: results of the randomized phase 2 STOP trial. Int J Radiat Oncol Biol Phys 121:28\u201338. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.08.031","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2776_CR10","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1186\/s12885-019-5977-6","volume":"19","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S et al (2019) Stereotactic ablative radiotherapy for the comprehensive treatment of 4\u201310 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer 19:816. https:\/\/doi.org\/10.1186\/s12885-019-5977-6","journal-title":"BMC Cancer"},{"key":"2776_CR11","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/s12885-020-06876-4","volume":"20","author":"R Olson","year":"2020","unstructured":"Olson R, Mathews L, Liu M et al (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of 1\u20133 oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial. BMC Cancer 20:380. https:\/\/doi.org\/10.1186\/s12885-020-06876-4","journal-title":"BMC Cancer"},{"key":"2776_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12885-021-07828-2","volume":"21","author":"S Thureau","year":"2021","unstructured":"Thureau S, Marchesi V, Vieillard MH et al (2021) Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS). BMC Cancer 21:117. https:\/\/doi.org\/10.1186\/s12885-021-07828-2","journal-title":"BMC Cancer"},{"key":"2776_CR13","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","volume":"17","author":"DR Gomez","year":"2016","unstructured":"Gomez DR, Blumenschein GR Jr, Lee JJ et al (2016) Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17:1672\u20131682. https:\/\/doi.org\/10.1016\/S1470-2045(16)30532-0","journal-title":"Lancet Oncol"},{"key":"2776_CR14","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/JCO.19.00201","volume":"37","author":"DR Gomez","year":"2019","unstructured":"Gomez DR, Tang C, Zhang J et al (2019) Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol 37:1558\u20131565. https:\/\/doi.org\/10.1200\/JCO.19.00201","journal-title":"J Clin Oncol"},{"key":"2776_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3501","volume":"4","author":"P Iyengar","year":"2018","unstructured":"Iyengar P, Wardak Z, Gerber DE et al (2018) Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 4:e173501. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3501","journal-title":"JAMA Oncol"},{"issue":"16_suppl","key":"2776_CR16","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1200\/JCO.2024.42.16_suppl.8506","volume":"42","author":"P Iyengar","year":"2024","unstructured":"Iyengar P, Hu C, Gomez DR et al (2024) Randomized phase II\/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 42(16_suppl):850. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.8506","journal-title":"J Clin Oncol"},{"issue":"6","key":"2776_CR17","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/jnci\/djac015","volume":"115","author":"XS Wang","year":"2023","unstructured":"Wang XS, Bai YF, Verma V et al (2023) Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer. J Natl Cancer Inst 115(6):742\u2013748. https:\/\/doi.org\/10.1093\/jnci\/djac015","journal-title":"J Natl Cancer Inst"},{"issue":"10422","key":"2776_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"CJ Tsai","year":"2024","unstructured":"Tsai CJ, Yang JT, Shaverdian N et al (2024) Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (consolidative use of radiotherapy to block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet 403(10422):171\u2013182. https:\/\/doi.org\/10.1016\/S0140-6736(23)01857-3","journal-title":"Lancet"},{"key":"2776_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2019.100126","volume":"19","author":"J Weiss","year":"2019","unstructured":"Weiss J, Kavanagh B, Deal A et al (2019) Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. Cancer Treat Res Commun 19:100126. https:\/\/doi.org\/10.1016\/j.ctarc.2019.100126","journal-title":"Cancer Treat Res Commun"},{"key":"2776_CR20","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1200\/JCO.2014.56.7412","volume":"32","author":"P Iyengar","year":"2014","unstructured":"Iyengar P, Kavanagh BD, Wardak Z et al (2014) Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol 32:3824\u20133830. https:\/\/doi.org\/10.1200\/JCO.2014.56.7412","journal-title":"J Clin Oncol"},{"key":"2776_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020690","volume":"8","author":"J Conibear","year":"2018","unstructured":"Conibear J, Chia B, Ngai Y et al (2018) Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. BMJ Open 8:e020690. https:\/\/doi.org\/10.1136\/bmjopen-2017-020690","journal-title":"BMJ Open"},{"key":"2776_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ctro.2021.12.008","volume":"33","author":"H Bahig","year":"2022","unstructured":"Bahig H, Tonneau M, Blais N et al (2022) Stereotactic ablative radiotherapy for oligo-progressive disease refractory to systemic therapy in non-small cell lung cancer: a registry-based phase II randomized trial (SUPPRESS-NSCLC). Clin Transl Radiat Oncol 33:115\u2013119. https:\/\/doi.org\/10.1016\/j.ctro.2021.12.008","journal-title":"Clin Transl Radiat Oncol"},{"key":"2776_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.radonc.2019.12.019","volume":"145","author":"E Pons-Tostivint","year":"2020","unstructured":"Pons-Tostivint E, Kirova Y, Lusque A et al (2020) Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysis. Radiother Oncol 145:109\u2013116. https:\/\/doi.org\/10.1016\/j.radonc.2019.12.019","journal-title":"Radiother Oncol"},{"key":"2776_CR24","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/archsurg.1992.01420110024006","volume":"127","author":"ED Staren","year":"1992","unstructured":"Staren ED, Salerno C, Rongione A et al (1992) Pulmonary resection for metastatic breast cancer. Arch Surg 127:1282\u20131284. https:\/\/doi.org\/10.1001\/archsurg.1992.01420110024006","journal-title":"Arch Surg"},{"key":"2776_CR25","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/0003-4975(94)91639-x","volume":"58","author":"ML McDonald","year":"1994","unstructured":"McDonald ML, Deschamps C, Ilstrup DM et al (1994) Pulmonary resection for metastatic breast cancer. Ann Thorac Surg 58:1599\u20131602. https:\/\/doi.org\/10.1016\/0003-4975(94)91639-x","journal-title":"Ann Thorac Surg"},{"key":"2776_CR26","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/j.1445-2197.1997.tb07116.x","volume":"67","author":"R Simpson","year":"1997","unstructured":"Simpson R, Kennedy C, Carmalt H et al (1997) Pulmonary resection for metastatic breast cancer. Aust N Z J Surg 67:717\u2013719. https:\/\/doi.org\/10.1111\/j.1445-2197.1997.tb07116.x","journal-title":"Aust N Z J Surg"},{"key":"2776_CR27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/s1010-7940(02)00331-7","volume":"22","author":"G Friedel","year":"2002","unstructured":"Friedel G, Pastorino U, Ginsberg RJ et al (2002) Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases. Eur J Cardiothorac Surg 22:335\u2013344. https:\/\/doi.org\/10.1016\/s1010-7940(02)00331-7","journal-title":"Eur J Cardiothorac Surg"},{"key":"2776_CR28","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1245\/ASO.2004.01.007","volume":"11","author":"G Vlastos","year":"2004","unstructured":"Vlastos G, Smith DL, Singletary SE et al (2004) Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol 11:869\u2013874. https:\/\/doi.org\/10.1245\/ASO.2004.01.007","journal-title":"Ann Surg Oncol"},{"key":"2776_CR29","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1245\/s10434-010-1016-1","volume":"17","author":"BA Pockaj","year":"2010","unstructured":"Pockaj BA, Wasif N, Dueck AC et al (2010) Metastasectomy and surgical resection of the primary tumor in patients with stage IV breast cancer: time for a second look? Ann Surg Oncol 17:2419\u20132426. https:\/\/doi.org\/10.1245\/s10434-010-1016-1","journal-title":"Ann Surg Oncol"},{"key":"2776_CR30","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.surg.2011.12.017","volume":"151","author":"DE Abbott","year":"2012","unstructured":"Abbott DE, Brouquet A, Mittendorf EA et al (2012) Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery 151:710\u2013716. https:\/\/doi.org\/10.1016\/j.surg.2011.12.017","journal-title":"Surgery"},{"key":"2776_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195149","volume":"13","author":"JC Hong","year":"2018","unstructured":"Hong JC, Ayala-Peacock DN, Lee J et al (2018) Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: a multi-institutional pooled analysis. PLoS ONE 13:e0195149. https:\/\/doi.org\/10.1371\/journal.pone.0195149","journal-title":"PLoS ONE"},{"key":"2776_CR32","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1053\/j.seminoncol.2014.09.016","volume":"41","author":"JK Salama","year":"2014","unstructured":"Salama JK, Chmura SJ (2014) The role of surgery and ablative radiotherapy in oligometastatic breast cancer. Semin Oncol 41:790\u2013797. https:\/\/doi.org\/10.1053\/j.seminoncol.2014.09.016","journal-title":"Semin Oncol"},{"key":"2776_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000358750","volume":"9","author":"S Di Lascio","year":"2014","unstructured":"Di Lascio S, Pagani O (2014) Oligometastatic breast cancer: a shift from palliative to potentially curative treatment? Breast Care (Basel) 9:7\u201314. https:\/\/doi.org\/10.1159\/000358750","journal-title":"Breast Care (Basel)"},{"key":"2776_CR34","doi-asserted-by":"publisher","first-page":"i58","DOI":"10.1093\/jrr\/rrw006","volume":"57","author":"U Ricardi","year":"2016","unstructured":"Ricardi U, Badellino S, Filippi AR (2016) Clinical applications of stereotactic radiation therapy for oligometastatic cancer patients: a disease-oriented approach. J Radiat Res 57:i58\u2013i68. https:\/\/doi.org\/10.1093\/jrr\/rrw006","journal-title":"J Radiat Res"},{"key":"2776_CR35","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.radonc.2017.08.032","volume":"126","author":"M Trovo","year":"2018","unstructured":"Trovo M, Furlan C, Polesel J et al (2018) Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial. Radiother Oncol 126:177\u2013180. https:\/\/doi.org\/10.1016\/j.radonc.2017.08.032","journal-title":"Radiother Oncol"},{"key":"2776_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.radonc.2018.11.022","volume":"131","author":"MT Milano","year":"2019","unstructured":"Milano MT, Katz AW, Zhang H et al (2019) Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: some patients survive longer than a decade. Radiother Oncol 131:45\u201351. https:\/\/doi.org\/10.1016\/j.radonc.2018.11.022","journal-title":"Radiother Oncol"},{"key":"2776_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.breast.2019.10.016","volume":"49","author":"S David","year":"2020","unstructured":"David S, Tan J, Savas P et al (2020) Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: a prospective clinical trial. Breast 49:55\u201362. https:\/\/doi.org\/10.1016\/j.breast.2019.10.016","journal-title":"Breast"},{"issue":"16","key":"2776_CR38","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1200\/JCO.2022.40.16_suppl.1007","volume":"40","author":"SJ Chmura","year":"2022","unstructured":"Chmura SJ, Winter KA, Woodward WA et al (2022) NRG-BR002: a phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). J Clin Oncol 40(16):1007. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.1007","journal-title":"J Clin Oncol"},{"key":"2776_CR39","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"LMS Boev\u00e9","year":"2019","unstructured":"Boev\u00e9 LMS, Hulshof MCCM, Vis AN et al (2019) Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary\u3042 bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol 75:410\u2013418. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.008","journal-title":"Eur Urol"},{"key":"2776_CR40","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392:2353\u20132366. https:\/\/doi.org\/10.1016\/S0140-6736(18)32486-3","journal-title":"Lancet"},{"key":"2776_CR41","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36:446\u2013453. https:\/\/doi.org\/10.1200\/JCO.2017.75.4853","journal-title":"J Clin Oncol"},{"key":"2776_CR42","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.eururo.2018.06.004","volume":"74","author":"S Siva","year":"2018","unstructured":"Siva S, Bressel M, Murphy DG et al (2018) Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol 74:455\u2013462. https:\/\/doi.org\/10.1016\/j.eururo.2018.06.004","journal-title":"Eur Urol"},{"key":"2776_CR43","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M et al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 6:650\u2013659. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0147","journal-title":"JAMA Oncol"},{"key":"2776_CR44","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/ijc.32509","volume":"146","author":"P Bowden","year":"2020","unstructured":"Bowden P, See AW, Frydenberg M et al (2020) Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial. Int J Cancer 146:161\u2013168. https:\/\/doi.org\/10.1002\/ijc.32509","journal-title":"Int J Cancer"},{"key":"2776_CR45","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.eururo.2021.02.031","volume":"80","author":"RM Glicksman","year":"2021","unstructured":"Glicksman RM, Metser U, Vines D et al (2021) Curative-intent metastasis-directed therapies for molecularly-defined oligorecurrent prostate cancer: a prospective phase II trial testing the oligometastasis hypothesis. Eur Urol 80:374\u2013382. https:\/\/doi.org\/10.1016\/j.eururo.2021.02.031","journal-title":"Eur Urol"},{"key":"2776_CR46","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.ijrobp.2020.05.003","volume":"108","author":"Q Liu","year":"2020","unstructured":"Liu Q, Zhu Z, Chen Y et al (2020) Phase 2 study of stereotactic body radiation therapy for patients with oligometastatic esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 108:707\u2013715. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.05.003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2776_CR47","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/S1470-2045(21)00528-3","volume":"22","author":"C Tang","year":"2021","unstructured":"Tang C, Msaouel P, Hara K et al (2021) Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol 22:1732\u20131739. https:\/\/doi.org\/10.1016\/S1470-2045(21)00528-3","journal-title":"Lancet Oncol"},{"key":"2776_CR48","doi-asserted-by":"publisher","first-page":"3795","DOI":"10.1200\/JCO.24.00081","volume":"42","author":"EB Ludmir","year":"2024","unstructured":"Ludmir EB, Sherry AD, Fellman BM et al (2024) Addition of metastasis-directed therapy to systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): a multicenter, randomized phase II trial. J Clin Oncol 42:3795\u20133805. https:\/\/doi.org\/10.1200\/JCO.24.00081","journal-title":"J Clin Oncol"},{"key":"2776_CR49","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jhep.2024.02.022","volume":"81","author":"SH Choi","year":"2024","unstructured":"Choi SH, Seong J (2024) Stereotactic ablative radiotherapy for patients with oligometastatic hepatocellular carcinoma: a prospective phase 2 trial. J Hepatol 81:84\u201392. https:\/\/doi.org\/10.1016\/j.jhep.2024.02.022","journal-title":"J Hepatol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02776-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02776-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02776-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T07:37:12Z","timestamp":1753429032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02776-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2776"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02776-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]},"assertion":[{"value":"9 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}